Onken Julia, Friesen Claudia, Vajkoczy Peter, Misch Martin
Department of Neurosurgery, Charité University of Berlin, Berlin, Germany
Berlin Institute of Health, Berlin, Germany.
Anticancer Res. 2017 Mar;37(3):1227-1235. doi: 10.21873/anticanres.11438.
BACKGROUND/AIM: D,L-Methadone increases sensitivity toward chemotherapy of different tumor cell populations. We evaluated the safety and tolerance of additional use of D,L-methadone in patients with glioma in combination with chemotherapy.
The dosage, duration of therapy and side-effects related to D,L-methadone were recorded in 27 patients. Toxicity was assessed accordingly to the Common Toxicity Criteria (CTC) of the National Cancer Institute. Progression-free survival at 6 months (PFS-6) was assessed.
A total of 13 patients reported grade 1-3 nausea at the beginning of the D,L-methadone therapy. Four patients reported persistent side-effects of nausea (CTC Grade 2, n=1) and obstipation (CTC grade 2-3, n=3). PFS-6 of patients with glioblastoma was 80% in those with non-methylated O-methylguanine-DNA methyltransferase (MGMT) (n=5) and 100% in those with MGMT methylation (n=7).
D,L-methadone can be safely combined with standard glioma chemotherapy without increasing the risk of toxicity or vegetative symptoms such as tachycardia, sweating and restlessness. PFS-6 in patients with primary glioblastoma treated this way seems to be at least comparable to that of historic controls.
背景/目的：消旋美沙酮可提高不同肿瘤细胞群体对化疗的敏感性。我们评估了消旋美沙酮联合化疗在胶质瘤患者中额外使用的安全性和耐受性。
记录了27例患者使用消旋美沙酮的剂量、治疗持续时间及相关副作用。根据美国国立癌症研究所的通用毒性标准（CTC）评估毒性。评估了6个月时的无进展生存期（PFS-6）。
共有13例患者在消旋美沙酮治疗开始时报告有1-3级恶心。4例患者报告有持续性恶心副作用（CTC 2级，n = 1）和便秘（CTC 2-3级，n = 3）。胶质母细胞瘤患者中，O-甲基鸟嘌呤-DNA甲基转移酶（MGMT）未甲基化者（n = 5）的PFS-6为80%，MGMT甲基化者（n = 7）的PFS-6为100%。
消旋美沙酮可安全地与标准胶质瘤化疗联合使用，而不会增加毒性风险或出现如心动过速、出汗和烦躁不安等植物神经症状。以这种方式治疗的原发性胶质母细胞瘤患者的PFS-6似乎至少与历史对照相当。
